UY28817A1 - Compuestos de imidazol para el tratamiento de trastornos neurodegerativos - Google Patents

Compuestos de imidazol para el tratamiento de trastornos neurodegerativos

Info

Publication number
UY28817A1
UY28817A1 UY28817A UY28817A UY28817A1 UY 28817 A1 UY28817 A1 UY 28817A1 UY 28817 A UY28817 A UY 28817A UY 28817 A UY28817 A UY 28817A UY 28817 A1 UY28817 A1 UY 28817A1
Authority
UY
Uruguay
Prior art keywords
compounds
treatment
disorders
formula
imidazol compounds
Prior art date
Application number
UY28817A
Other languages
English (en)
Inventor
Michael Aaron Brodney
Karen Jean Coffman
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY28817A1 publication Critical patent/UY28817A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a los compuestos de fórmula I en la que R1, R2, R3, R4, R6, R7, y A son como se han definido. Los compuestos de la fórmula I tienen actividad en la inhibición de la producción de ABeta-péptidos. La invención también se refiere a las composiciones y procedimientos farmacéuticos para tratar enfermedades y trastornos, por ejemplo, trastornos neurodegenerativos y/o neurológicos, por ejemplo enfermedad de Alzheimer, en un mamífero que comprende los compuestos de la fórmula I.
UY28817A 2004-03-23 2005-03-22 Compuestos de imidazol para el tratamiento de trastornos neurodegerativos UY28817A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55562304P 2004-03-23 2004-03-23

Publications (1)

Publication Number Publication Date
UY28817A1 true UY28817A1 (es) 2005-10-31

Family

ID=34961257

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28817A UY28817A1 (es) 2004-03-23 2005-03-22 Compuestos de imidazol para el tratamiento de trastornos neurodegerativos

Country Status (43)

Country Link
US (3) US7342118B2 (es)
EP (1) EP1730119B1 (es)
JP (2) JP4054845B2 (es)
KR (1) KR100814599B1 (es)
CN (1) CN1934091B (es)
AP (1) AP2379A (es)
AR (1) AR049875A1 (es)
AT (1) ATE399155T1 (es)
AU (1) AU2005225635B2 (es)
BR (1) BRPI0509069B8 (es)
CA (1) CA2560580C (es)
CR (1) CR8644A (es)
CY (1) CY1108347T1 (es)
DE (1) DE602005007717D1 (es)
DK (1) DK1730119T3 (es)
DO (1) DOP2005000040A (es)
EA (1) EA011689B1 (es)
EC (1) ECSP066879A (es)
ES (1) ES2308441T3 (es)
GE (1) GEP20084420B (es)
GT (1) GT200500060A (es)
HK (1) HK1099756A1 (es)
HN (1) HN2005000115A (es)
HR (1) HRP20080375T3 (es)
IL (1) IL177594A0 (es)
IS (1) IS8550A (es)
MA (1) MA28481B1 (es)
NL (1) NL1028598C2 (es)
NO (1) NO338263B1 (es)
NZ (1) NZ549331A (es)
PA (1) PA8627201A1 (es)
PE (1) PE20051155A1 (es)
PL (1) PL1730119T3 (es)
PT (1) PT1730119E (es)
RS (1) RS50595B (es)
SI (1) SI1730119T1 (es)
SV (1) SV2006002055A (es)
TN (1) TNSN06300A1 (es)
TW (1) TWI372146B (es)
UA (1) UA83899C2 (es)
UY (1) UY28817A1 (es)
WO (1) WO2005092864A1 (es)
ZA (1) ZA200606957B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084420B (en) 2004-03-23 2008-07-10 Pfizer Prod Inc Use of imidazole compounds for the treatment of neurodegenerative disorders
KR20080040010A (ko) * 2005-09-22 2008-05-07 화이자 프로덕츠 인코포레이티드 신경계 질환 치료용 이미다졸 화합물
AU2007207743B2 (en) 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
DE102006048042A1 (de) * 2006-10-11 2008-04-17 Bayer Healthcare Ag Acylaminoimidazole und Acylaminothiazole
WO2009052116A1 (en) * 2007-10-15 2009-04-23 The Salk Institute For Biological Studies Methods for treating a variety of diseases and conditions, and compounds useful therefor
US20110021625A1 (en) * 2008-01-23 2011-01-27 Lead Chemical Co., Ltd. Neuronal cell death inhibitor
WO2010096371A2 (en) 2009-02-18 2010-08-26 Boehringer Ingelheim International Gmbh Heterocyclic compounds which modulate the cb2 receptor
WO2010100606A1 (en) * 2009-03-03 2010-09-10 Pfizer Inc. Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
JP5746764B2 (ja) 2010-07-22 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
RU2465273C2 (ru) * 2010-08-31 2012-10-27 Общество С Ограниченной Ответственностью "Биофарм-Меморейн" ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
EP2763676B1 (en) 2011-10-03 2019-12-25 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
WO2015092614A1 (en) 2013-12-20 2015-06-25 Pfizer Inc. Activating notch alterations in breast cancer
CN107406445B (zh) 2015-02-03 2019-12-24 辉瑞公司 新颖环丙苯并呋喃基吡啶并吡嗪二酮类
WO2016208591A1 (ja) * 2015-06-22 2016-12-29 大日本住友製薬株式会社 １，４－ジ置換イミダゾール誘導体
JPWO2016208592A1 (ja) 2015-06-22 2018-04-05 大日本住友製薬株式会社 二環性複素環アミド誘導体
US10898469B2 (en) 2016-02-26 2021-01-26 Sumitomo Dainippon Pharma Co., Ltd. Imidazolylamide derivative
MX2018011102A (es) 2016-03-15 2019-01-10 Oryzon Genomics Sa Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN112384531B (zh) 2018-06-01 2024-05-14 诺华股份有限公司 针对bcma的结合分子及其用途
US20210196681A1 (en) * 2018-08-27 2021-07-01 Universiteit Maastricht Selective presenilin-2 gamma-secretase inhibitors
TW202115114A (zh) 2019-06-24 2021-04-16 瑞士商諾華公司 針對靶向ｂ細胞成熟抗原的多特異抗體之給藥方案及組合療法
US11884634B2 (en) 2019-08-09 2024-01-30 Pfizer Inc. Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
US10590087B1 (en) 2019-08-09 2020-03-17 Pfizer Inc. Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
CN114555562A (zh) * 2019-08-09 2022-05-27 辉瑞公司 (s)-2-(((s)-6,8-二氟-1,2,3,4-四氢萘-2-基)氨基)-n-(1-(2-甲基-1-(新戊基氨基)丙-2-基)-1h-咪唑-4-基)戊酰胺的固态形式及其用途
CN114466844A (zh) * 2019-10-02 2022-05-10 康佳诺医疗科技发展有限公司 N-(1h-咪唑-2-基)苯甲酰胺化合物及包含其作为活性成分的药物组合物
KR20230008197A (ko) 2020-05-13 2023-01-13 화이자 인코포레이티드 암을 치료하기 위한 방법, 요법 및 용도
WO2022053990A1 (en) 2020-09-14 2022-03-17 Pfizer Inc. Methods, therapies and uses for treating cancer
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
US20240041884A1 (en) 2020-12-07 2024-02-08 Cellestia Biotech Ag Pharmaceutical Combinations for Treating Cancer
TW202313020A (zh) 2021-06-02 2023-04-01 瑞士商西萊絲蒂亞生物科技股份有限公司 自體免疫及發炎性疾病的治療方法
AR126961A1 (es) 2021-09-01 2023-12-06 Springworks Therapeutics Inc Sintesis de nirogacestat
US11504354B1 (en) 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions
EP4429661A1 (en) 2021-11-08 2024-09-18 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
EP4436958A1 (en) * 2021-11-23 2024-10-02 Teva Pharmaceuticals International GmbH Solid state forms of nirogacestat salts
EP4223292A1 (en) 2022-02-07 2023-08-09 Cellestia Biotech AG Pharmaceutical combinations for treating cancer
WO2023174390A1 (zh) * 2022-03-17 2023-09-21 苏州科睿思制药有限公司 尼罗司他二氢溴酸盐的晶型及其制备方法和用途
US20230372301A1 (en) 2022-05-20 2023-11-23 Springworks Therapeutics, Inc. Treatments with nirogacestat
US12036207B2 (en) 2022-05-20 2024-07-16 Springworks Therapeutics, Inc. Treatments with nirogacestat
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512A (en) * 1846-05-09 Smut-machine
US50314A (en) * 1865-10-03 Improvement in telegraph-cables
DE1236426B (de) * 1960-08-25 1967-03-09 Dolomitwerke Gmbh Verfahren zur Wasseraufbereitung
US5401851A (en) 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
JPH07101958A (ja) 1992-10-16 1995-04-18 Takeda Chem Ind Ltd セフェム化合物、その製造法および抗菌組成物
DE19629816A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
ZA987383B (en) 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
CO5160260A1 (es) * 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
DE10019755A1 (de) 2000-04-20 2001-11-08 Bayer Ag Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
JP2002059707A (ja) * 2000-08-23 2002-02-26 Bridgestone Corp 空気入りタイヤ及び空気入りタイヤの製造方法
JP2004513935A (ja) 2000-11-17 2004-05-13 ノボ　ノルディスク　アクティーゼルスカブ グルカゴンアンタゴニスト／逆アゴニスト
TW200301698A (en) 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
JP2005518391A (ja) 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Ｇｋ活性化剤としてのアミド誘導体
CA2487976C (en) 2002-06-05 2011-07-26 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
CA2501799C (en) 2002-10-09 2008-06-17 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
CN1688557A (zh) 2002-10-09 2005-10-26 辉瑞产品公司 用于治疗神经变性疾病的噻唑化合物
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
MXPA05012196A (es) 2003-05-12 2006-02-08 Pfizer Prod Inc Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
BRPI0413245A (pt) 2003-08-01 2006-10-03 Pfizer Prod Inc compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
WO2005016267A2 (en) 2003-08-06 2005-02-24 Pfizer Products Inc. Oxazole compounds for the treatment of neurodegenerative disorders
CA2534532A1 (en) 2003-08-21 2005-03-10 Pfizer Products, Inc. Compounds for the treatment of neurodegenerative disorders
US7348968B2 (en) * 2003-12-02 2008-03-25 Sony Corporation Wireless force feedback input device
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
GEP20084420B (en) 2004-03-23 2008-07-10 Pfizer Prod Inc Use of imidazole compounds for the treatment of neurodegenerative disorders
US20050222227A1 (en) 2004-04-01 2005-10-06 Pfizer Inc Oxazole-amine compounds for the treatment of neurodegenerative disorders
US7309709B2 (en) 2004-04-01 2007-12-18 Pfizer Inc. Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders
US7232820B2 (en) 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
US7220865B2 (en) 2004-04-01 2007-05-22 Pfizer Inc Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
US7384968B2 (en) 2004-04-01 2008-06-10 Pfizer Inc. Thiazole-amine compounds for the treatment of neurodegenerative disorders
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
KR20080040010A (ko) * 2005-09-22 2008-05-07 화이자 프로덕츠 인코포레이티드 신경계 질환 치료용 이미다졸 화합물

Also Published As

Publication number Publication date
IS8550A (is) 2006-10-09
ZA200606957B (en) 2008-03-26
BRPI0509069A (pt) 2007-08-21
CR8644A (es) 2006-11-01
CY1108347T1 (el) 2014-02-12
AR049875A1 (es) 2006-09-13
HN2005000115A (es) 2009-04-20
CA2560580A1 (en) 2005-10-06
BRPI0509069B8 (pt) 2021-05-25
US20080227781A1 (en) 2008-09-18
WO2005092864A1 (en) 2005-10-06
US20050215610A1 (en) 2005-09-29
DOP2005000040A (es) 2005-10-21
US7951958B2 (en) 2011-05-31
GT200500060A (es) 2005-10-24
BRPI0509069B1 (pt) 2019-07-02
AU2005225635B2 (en) 2010-06-24
CN1934091B (zh) 2012-02-08
TW200539875A (en) 2005-12-16
AU2005225635A1 (en) 2005-10-06
AP2006003727A0 (en) 2006-10-31
HK1099756A1 (en) 2007-08-24
DK1730119T3 (da) 2008-08-11
PT1730119E (pt) 2008-09-02
ECSP066879A (es) 2006-11-24
US7795447B2 (en) 2010-09-14
EP1730119A1 (en) 2006-12-13
EP1730119B1 (en) 2008-06-25
JP2007291123A (ja) 2007-11-08
SI1730119T1 (sl) 2008-10-31
DE602005007717D1 (de) 2008-08-07
HRP20080375T3 (en) 2008-09-30
RS50595B (sr) 2010-05-07
SV2006002055A (es) 2006-05-09
KR100814599B1 (ko) 2008-03-17
NL1028598C2 (nl) 2006-01-03
ES2308441T3 (es) 2008-12-01
KR20060123651A (ko) 2006-12-01
UA83899C2 (uk) 2008-08-26
TWI372146B (en) 2012-09-11
NO20064726L (no) 2006-12-22
JP4054845B2 (ja) 2008-03-05
JP2007530525A (ja) 2007-11-01
NZ549331A (en) 2010-08-27
GEP20084420B (en) 2008-07-10
US20100168107A1 (en) 2010-07-01
US7342118B2 (en) 2008-03-11
NO338263B1 (no) 2016-08-08
AP2379A (en) 2012-03-08
ATE399155T1 (de) 2008-07-15
EA011689B1 (ru) 2009-04-28
NL1028598A1 (nl) 2005-09-26
CA2560580C (en) 2008-12-23
CN1934091A (zh) 2007-03-21
IL177594A0 (en) 2006-12-10
MA28481B1 (fr) 2007-03-01
PE20051155A1 (es) 2006-01-28
PA8627201A1 (es) 2005-12-23
TNSN06300A1 (fr) 2007-12-03
EA200601494A1 (ru) 2007-02-27
PL1730119T3 (pl) 2008-10-31

Similar Documents

Publication Publication Date Title
UY28817A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegerativos
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
UY28825A1 (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos
UY28450A1 (es) Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos.
UY28484A1 (es) Compuestos para el tratamiento de trastornos neurodegenerativos
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
BRPI0509504A (pt) compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CR9815A (es) Compuestos de imidazol para el tratamiento de transtornos neurologicos
BRPI0509559A (pt) compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos
UY28458A1 (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
BRPI0509582A (pt) compostos de tiazol-amina e respectivas composições farmacêuticas
WO2005095361A8 (en) Isoxazole- and isothiazole-amine compounds for the treatment of neurodegenerative disorders
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
DOP2006000200A (es) Compuestos de imidazol para el tratamiento de trastonos neurologicos
CU23591B7 (es) Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos
DOP2004000982A (es) Compuestos para el tratamiento de trastornos neurodegenerativos
DOP2004000970A (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
DOP2004000966A (es) Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos
BRPI0402756A (pt) método para o tratamento de distúrbios cognitivos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160502